R&D accounting and the tradeoff between relevance and objectivity

被引:104
作者
Healy, PM [1 ]
Myers, SC
Howe, CD
机构
[1] Harvard Univ, Sch Business, Cambridge, MA 02138 USA
[2] MIT, Sloan Sch Management, Cambridge, MA 02139 USA
关键词
D O I
10.1111/1475-679X.00067
中图分类号
F8 [财政、金融];
学科分类号
0202 ;
摘要
We rise a simulation model for a pharmaceutical R&D program to examine the tradeoff between objectivity and relevance of accounting information under various methods of R&D reporting. A simple capitalization rule, similar to the successful-efforts method of capitalizing oil and gas exploration costs, provides a stronger relation between accounting information and economic values than immediate expensing of R&D outlays or capitalizing the full cost of outlays. The superior relevance of this "successful-efforts" method persists even when earnings management is widespread.
引用
收藏
页码:677 / 710
页数:34
相关论文
共 33 条
[1]   COMPARATIVE SIMULATION OF GERMAN AND UNITED-STATES ACCOUNTING PRINCIPLES [J].
ABEL, R .
JOURNAL OF ACCOUNTING RESEARCH, 1969, 7 (01) :1-11
[2]  
BABER WR, 1991, ACCOUNTING BASED MEA
[3]  
BEAVER WH, 1979, ACCOUNT REV, V64, P38
[4]  
BUBLITZ B, 1989, ACCOUNT REV, V64, P108
[5]   Earnings management to avoid earnings decreases and losses [J].
Burgstahler, D ;
Dichev, I .
JOURNAL OF ACCOUNTING & ECONOMICS, 1997, 24 (01) :99-126
[6]   CORPORATE RESEARCH-AND-DEVELOPMENT EXPENDITURES AND SHARE VALUE [J].
CHAN, SH ;
MARTIN, JD ;
KENSINGER, JW .
JOURNAL OF FINANCIAL ECONOMICS, 1990, 26 (02) :255-276
[7]  
CHANG J, 1998, UNPUB DECLINE VALUE
[8]  
Dechow P.M., 1996, Contemporary Accounting Research, V13, P1, DOI 10.1111/j.1911-3846.1996.tb00489.x
[9]   RESEARCH-AND-DEVELOPMENT COSTS FOR NEW DRUGS BY THERAPEUTIC CATEGORY - A STUDY OF THE UNITED-STATES PHARMACEUTICAL-INDUSTRY [J].
DIMASI, JA ;
HANSEN, RW ;
GRABOWSKI, HG ;
LASAGNA, L .
PHARMACOECONOMICS, 1995, 7 (02) :152-169
[10]   SUCCESS RATES FOR NEW DRUGS ENTERING CLINICAL-TESTING IN THE UNITED-STATES [J].
DIMASI, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :1-14